PLXNA2

Across TCGA pan-cancer cohorts, PLXNA2 Mutation is linked to patient survival in 12 of 34 cancer types, making it a survival-associated PLXNA2 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher PLXNA2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PLXNA2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

THYM, ACC, and UCEC are the cancer types where PLXNA2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
ACC	DFS	Median	All	0.039	0.778	<.001	36	view →
UCEC	DFS	Median	III,IV	0.928	0.528	.019	22	view →
ESCA	OS	Median	II,III,IV	0.103	0.868	<.001	18	view →
STAD	DFS	Median	All	1.000	0.645	.015	14	view →
LUAD	OS	Median	II,III,IV	0.364	0.714	.005	12	view →
BLCA	DFS	Median	IV	0.663	0.192	.030	12	view →
CESC	DFS	Median	II,III,IV	1.000	0.440	.026	8	view →
LUSC	DFS	Median	All	0.944	0.650	.019	8	view →
SKCM	OS	Median	All	0.390	0.783	.009	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
SARC	DFS	Median	All	0.121	0.591	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

PLXNA2–THYM (OS)

Open the THYM breakdown →